- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00504907
Safety Study of Oral BTA9881 to Treat RSV Infection
May 29, 2018 updated by: Biota Scientific Management Pty Ltd
A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Nucleus Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and female subjects >=18 and <=45 years of age.
- Individuals who have freely given Informed Consent in writing.
- Male subjects should use appropriate contraception (e.g. condoms) during the time interval between dosing until three months after dosing. Female subjects must be surgically sterile or post-menopausal (defined as at least two years post cessation of menses and/or follicle-stimulating hormone (FSH) >18 mIU/mL and serum oestradiol <110 pmol/L), or must agree to use two forms of the following contraception: oral contraceptives, or other forms of hormonal birth control including hormonal vaginal rings or transdermal patches, intra-uterine devices, condoms, and spermicide during the time interval between dosing until three months after dosing. Female subjects must also be non-lactating and have a negative serum pregnancy test at screening and at baseline.
- Able to perform nasal wash procedure.
- Normotensive (systolic BP ≤ 140 mm Hg and diastolic BP ≤ 90 mm Hg).
- No abnormal finding of clinical relevance at the screening examination that the Investigator considers might interfere with the objectives of this clinical trial.
- No clinically relevant abnormality in the ECG; QTc <430 ms (males) or <450 ms (females).
- Healthy based on medical history, physical examination, 12-lead ECG and clinical laboratory tests, and with no disease that the Investigator regards as clinically relevant.
- Negative results in Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface antigen (HBsAg) and Hepatitis C antibody tests.
- Willingness to abstain from alcohol and caffeine-containing food and beverages for 48 hours prior to dosing and for the duration of the clinical trial.
Exclusion Criteria:
- Use of any prescription medication (other than allowable oral contraceptives and implanted hormonal contraceptives) during the 14 days prior to dosing.
- Use of any non-prescription ('over the counter') product, including herbal products, diet aids, hormone supplements, etc., within 14 days prior to dosing.
- Intake of any investigational drug within 3 months prior to dosing.
- History or clinical evidence of significant cardiovascular disease (including risk factors for cardiac arrhythmias) or a previous history of any cardiovascular condition that, in the opinion of the investigator, would interfere with the conduct of the trial.
- History or clinical evidence of significant cerebrovascular, cardiovascular, gastrointestinal, or haematological disease, or myocardial infarction, or a previous history of any other serious underlying disease (including immunocompromised subjects and/or neutropenic subjects) that, in the opinion of the investigator would interfere with the conduct of the clinical trial.
- History or clinical evidence of significant respiratory disease (including asthma, chronic obstructive pulmonary disease, cystic fibrosis and/or recurrent lower respiratory tract infection), or upper respiratory tract infection within the last month or lower respiratory tract infection within the last three months.
- History or clinical evidence of renal disease (including renovascular occlusive disease), nephrectomy and/or renal transplant, and/or previous clinically significant laboratory abnormalities of renal function parameters. All subjects with serum creatinine or proteinuria outside the normal laboratory reference range at screening and baseline that are regarded by the Investigator as clinically significant.
- History or clinical evidence of hepatic disease and/or previous clinically significant laboratory abnormalities of liver function parameters. All subjects with bilirubin, gamma glutamyl transferase (GGT), alanine transaminase (ALT), and aspartate transaminase (AST) outside the normal laboratory reference range at screening and baseline, that are regarded by the Investigator as clinically significant. Subjects known to have experienced elevated liver enzyme values in previous clinical studies will also be excluded.
- History or clinical evidence of adrenal disease (including Cushing's Syndrome or Addison's disease) or thyroid disease (including hyper or hypothyroidism), and/or previous clinically significant laboratory abnormalities of adrenal or thyroid function parameters. All subjects with thyroid function (TSH, FT4, FT3) outside the normal laboratory reference range at baseline and regarded by the Investigator as clinically significant.
- Psychiatric or emotional problems that would invalidate the giving of Informed Consent or limit the ability of the subject to comply with clinical trial requirements.
- Body Mass Index (BMI) ≤18.5 kg/m2 or >=30.0 kg/m2.
- History of alcohol and/or drug abuse within 1 year prior to screening (verified by drug screening).
- Receipt of blood or blood products, or loss of 450 mL or more of blood, during the last three months prior to dosing.
- Unwillingness or inability to provide Informed Consent or to participate satisfactorily for the entire clinical trial period.
- Subjects who smoke or have been non-smokers for less than 3 months prior to dosing.
- Subjects who were previously enrolled in this clinical trial.
- Poor veins, or fear of venipuncture or sight of blood, or known allergy or hypersensitivity to lidocaine.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Placebo or BTA9881 -10mg
|
Single oral escalating doses
|
Experimental: Cohort B
Placebo or BTA9881 - 10mg
|
Single oral escalating doses
|
Experimental: Cohort C
Placebo or BTA9881 - 25mg
|
Single oral escalating doses
|
Experimental: Cohort D
Placebo or BTA9881 - 50mg
|
Single oral escalating doses
|
Experimental: Cohort E
Placebo or BTA9881 - 100mg
|
Single oral escalating doses
|
Experimental: Cohort F
Placebo or BTA9881 - 200mg
|
Single oral escalating doses
|
Experimental: Cohort G
Placebo or BTA9881 - 400mg
|
Single oral escalating doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the safety and tolerability of ascending single oral doses of BTA9881 in healthy adult subjects.
Time Frame: Two weeks
|
Two weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the pharmacokinetics and dose proportionality of BTA9881 after a single oral dose in healthy adult subjects
Time Frame: Two weeks
|
Two weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
July 18, 2007
First Submitted That Met QC Criteria
July 18, 2007
First Posted (Estimate)
July 20, 2007
Study Record Updates
Last Update Posted (Actual)
May 30, 2018
Last Update Submitted That Met QC Criteria
May 29, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTA9881-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Virus Infections
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus ImmunizationPuerto Rico, United States, Australia, Honduras, Mexico
-
EuBiologics Co.,LtdNot yet recruitingRespiratory Syncytial Virus Infections | Respiratory Syncytial Virus (RSV)
-
Clover Biopharmaceuticals AUS Pty LtdRecruitingRespiratory Syncytial Virus InfectionAustralia
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionChina
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus Infection
-
Sanofi Pasteur, a Sanofi CompanyRecruitingRespiratory Syncytial Virus InfectionUnited States, Puerto Rico
-
PfizerCompletedRespiratory Syncytial Virus InfectionChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedRespiratory Syncytial Virus InfectionHonduras, United States, Chile
-
AbbVie (prior sponsor, Abbott)CompletedRespiratory Syncytial Virus InfectionJapan
-
Shanghai Ark Biopharmaceutical Co., Ltd.Ark Biosciences Pty Ltd.CompletedRESPIRATORY SYNCYTIAL VIRUS INFECTIONSAustralia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States